Zobrazení zdroje stránky Thestruptruelsen7766

6% and 3.6%. Four patients in the AAD group developed paraplegia and permanent stroke rate was significantly higher in AAD compared to non-AAD patients (17.3% <br /><br /> 2.8%; P=0.034). One, 3- and 5-year survival rates were 78.7%±4.0%, 72.2%±4.8%, and 64.3%±6.8% for the total cohort; survival at 1-, 3- and 5-year was 76.7%±5.0%, 71.0%±6.1%, and 64.5%±8.3% for the AAD cohort compared to 83.1%±6.3%, 75.0%±7.9% and 66.7% for non-AAD patients (P=0.579), respectively.<br /><br /> Our single-center experience confirms good early and mid-term survival after the FET procedure in patients presenting with AAD, CAD and aneurysm. Future efforts should focus on reduction of severe neurological complication.<br /><br />Our single-center experience confirms good early and mid-term survival after the FET procedure in patients presenting with AAD, CAD and aneurysm. Future efforts should focus on reduction of severe neurological complication.<br /><br /> Second primary lung cancer (SPLC) occurs not rarely in recent years. The effect of radiotherapy on SPLC remains unclear. This study aims to explore the survival outcome of SPLC patients with clinical stage T1 lung cancer previously treated with radiotherapy.<br /><br /> A total of 705 SPLC patients that previously underwent radiotherapy for first primary lung cancer (FPLC) were identified from the Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2016. Univariate and multivariate Cox regression analyses were performed to find prognostic factors. The survival outcomes were plotted using Kaplan-Meier (KM) method and compared by log-rank test. Additionally, propensity score matching (PSM) analyses were used to compare overall survival (OS) and lung cancer-specific survival (CSS) between radiotherapy and other treatment groups for SPLC.<br /><br /> According to Cox analyses, age &gt;62 years [hazard ratio (HR) 1.48, 95% confidence interval (CI) 1.10-1.99; P=0.010], SPLC tumor size &gt;1 cm (HR 1.95, 95% CI 1.51-2.53; P&lt;0.001), and treatments for SPLC as chemotherapy (HR 1.39, 95% CI 1.13-1.71; P=0.002), no surgery (HR 2.00, 95% CI 1.34-2.98; P=0.001) and no radiotherapy (HR 1.73, 95% CI 1.39-2.15; P&lt;0.001) independently indicated worse survival. After PSM, patients treated with radiotherapy for SPLC had significantly better OS and CSS than the none-treatment (OS P=0.004; CSS P&lt;0.001), chemotherapy (P&lt;0.001) or radiotherapy plus chemotherapy (OS P=0.032; CSS P=0.008) groups, but demonstrated a worse OS than the surgery group (P=0.034).<br /><br /> Surgery may be more beneficial to survival than radiotherapy and chemotherapy and should be considered first if possible. When patients cannot tolerate surgery, radiotherapy can be an effective alternative.<br /><br />Surgery may be more beneficial to survival than radiotherapy and chemotherapy and should be considered first if possible. When patients cannot tolerate surgery, radiotherapy can be an effective alternative.<br /><br /> Minimally invasive robotic-assisted thoracic surgery is an increasingly popular platform for oncological thoracic resection. The aim of this study is to evaluate the feasibility of completely portal robotic lobectomy for patients with early non-small cell lung cancer (NSCLC), analysing the perioperative and mid-term results.<br /><br /> This is a single-institution retrospective cohort study of consecutive patients who underwent completely portal robotic lobectomy for early stage NSCLC over a 53-month period.<br /><br /> A total of 59 consecutive patients were included in this study. Median operative time was 155 min (range, 80-313 min). Conversion rate was 13.6%. Median intensive care/high dependency unit stay, chest tube duration and length of hospital stay were 1 day (range, 0-4 days), 2 days (range, 1-20 days) and 4 days (range, 2-30 days) respectively; 98.2% of patients achieved R0 resection. Overall, 23.7% had minor complications. There was no perioperative (30-day) mortality in this study. Final pathological staging distribution was 55.9% stage 1A, 23.7% stage 1B, 10.2% stage 2A and 10.2% stage 2B; 23% were upstaged after pathological staging. Median follow-up was 33 months (range, 3-70 months). The 3-year overall survival and recurrence-free survival were 86.2% (95% CI, 72.0-96.8) and 69% (95% CI, 56.1-81.9) respectively. The 3-year overall survival and recurrence free survival for stage 1 patients were 88.4% (95% CI, 77.4-99.4) and 75.6% (95% CI, 62.3-88.9) respectively.<br /><br /> By clearly defining completely portal robotic lobectomy, it is possible to delivery promising perioperative and mid-term results for early stage primary lung cancer, even in a geographical location that has yet to assimilate this technology.<br /><br />By clearly defining completely portal robotic lobectomy, it is possible to delivery promising perioperative and mid-term results for early stage primary lung cancer, even in a geographical location that has yet to assimilate this technology.<br /><br /> We investigated the clinicoradiopathological features and prognosis according to genomic alterations in patients with surgically resected lung adenocarcinoma.<br /><br /> Patients who underwent surgical resection for pathologic stage I, II, or IIIA lung adenocarcinoma between 2009 and 2016 and for whom results regarding <br /><br /> mutation, ALK immunohistochemistry (IHC), and <br /><br /> mutation were available were included. Clinicoradiopathological characteristics, genomic alterations, and disease-free survival were analyzed retrospectively.<br /><br /> Of 164 patients, 86 (52.4%) were female and 94 (57.3%) were never-smokers. [https://www.selleckchem.com/products/ldn193189.html selleck chemical] The most common imaging patterns were part-solid lesion (67.7%) followed by solid (26.2%) and non-solid (6.1%) lesions. <br /><br /> mutation, ALK IHC, and <br /><br /> mutation were positive in 95 (57.9%), 9 (5.5%), and 11 (6.7%) patients, respectively. <br /><br /> mutation positivity was associated with female sex, never-smoker, subsolid pattern on radiological examination, and acinar or papillary predominant histologic subtype. ALK IHC positivity was associated with longer maximal diameter, advanced stage, solid pattern on radiological examination, solid predominant histologic subtype, and distant metastasis during follow-up. <br /><br /> mutation positivity was associated with male sex, smoker, solid pattern on radiological examination, and invasive mucinous adenocarcinoma on histologic analysis. In multivariable analysis, ALK IHC positivity and lymph node involvement were independently associated with recurrence. However, solidity was not an independent risk factor for recurrence.<br /><br /> Genomic alterations are associated with clinicoradiopathologic features in patients with resected lung adenocarcinoma. Identifying genomic alterations could help to predict the prognosis of early-stage lung adenocarcinoma.<br /><br />Genomic alterations are associated with clinicoradiopathologic features in patients with resected lung adenocarcinoma. Identifying genomic alterations could help to predict the prognosis of early-stage lung adenocarcinoma.